Arvinas (ARVN) Depreciation & Amortization (CF) (2017 - 2026)
Arvinas (ARVN) recorded quarterly Depreciation & Amortization (CF) of $700000.0 in Q1 2026, little changed quarter-over-quarter from $700000.0 in Q4 2025, and little changed on a YoY basis from $700000.0 in Q1 2025.
Arvinas (ARVN) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Arvinas' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $700000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed 0.0% year-over-year to $700000.0; the TTM figure through Mar 2026 stood at $3.0 million (down 26.83% YoY), while the FY2025 annual figure was $3.0 million, down 34.78% from the prior year.
- Depreciation & Amortization (CF) was $700000.0 for Q1 2026 at Arvinas, roughly flat from $700000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.7 million in Q4 2022 to a low of $700000.0 in Q1 2025.
- Historically, Depreciation & Amortization (CF) has averaged $1.1 million across 5 years, with a median of $1.2 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 36.36% in 2022, then slumped 41.67% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.7 million in 2022, then declined by 29.41% to $1.2 million in 2023, then retreated by 8.33% to $1.1 million in 2024, then slumped by 36.36% to $700000.0 in 2025, then changed by 0.0% to $700000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $700000.0 (Q1 2026), $700000.0 (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 700,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 700,000.00 |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Dec 31, 2025 | 700,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 1.20 Mn |
| Dec 31, 2023 | 1.20 Mn |